司库奇尤单抗治疗重度斑块型银屑病伴肝功能异常患者的临床观察OA

Objective To observe the efficacy of secukinumab in the treatment of severe plaque psoriasis with abnormal liver function and the changes in liver function after the treatment.Methods Seven patients with severe plaque psoriasis with abnormal liver function were subcuta-neously given secukinumab 300 mg/time,once-weekly from weeks 0 to 4,followed by once every 4 weeks.Routine blood test,liver and kidney functions,blood lipids and glucose were tested at weeks 1,2,3,and 4,and every 4 weeks thereafter until week 32.At the same time,the psoriat-ic lesion area and severity index(PASI),physician global assessment(PGA),and dermatology life quality index(DLQI)were recorded to assess the efficacy and safety.Results The PASI scores,PGA scores and DLQI were changed significantly from the baseline at all time points(P＜0.001).The PASI scores were significantly lower than the baseline scores at week 1(all P＜0.05)and rapidly declined in the first 4 weeks,with a linear decline over time(F=233.08,P＜0.001).Similarly,PGA scores were significantly lower than the baseline scores after 8-week treatments(all P＜0.05),with a linear decline from weeks 3 to 16(F=81.04,P＜0.001).Moreover,DLQI scores rapidly declined in the first 2 weeks of treatment,with a significant de-crease at week 12(all P＜0.05).DLQI scores linearly declined over time(F=71.09,P=0.001).However,no significant changes were observed in liver function,blood lipid profile,blood glucose level and renal function at any time points following the treatments.All patients did not show serious adverse drug reactions during the treatment.Conclusion Secukinumab is effec-tive and safe for patients with severe plaque psoriasis with abnormal liver function.